Clinical-stage biotechnology company developing precision therapies for autoimmune and inflammatory diseases, led by Afimetoran, an oral TLR7/TLR8 inhibitor.
Beeline Medicines is a clinical-stage biotechnology company developing precision therapies for autoimmune and inflammatory diseases. Founded in 2025 and based in the United States, the company works across immunology, small-molecule drug discovery and biologic therapies, with an approach grounded in validated biology and selective molecular properties.
Its lead program, Afimetoran, is a selective, oral, once-daily small-molecule inhibitor of the TLR7 and TLR8 immune receptors, being developed to restore immune homeostasis. The program has received FDA Fast Track designation for systemic lupus erythematosus. Four further disclosed programs round out the pipeline: BLN-326, an IL-2-CD25 fusion protein targeting regulatory T-cell biology; lomedeucitinib, an oral TYK2 inhibitor; BLN-481, an anti-IL-18 receptor beta antibody; and BLN-498, a myeloid-selective IL-10 therapeutic.
The company's work spans cytokine and receptor biology, precision medicine, clinical development and regulatory affairs. Its stated focus is on immune-mediated conditions, including systemic lupus erythematosus and atopic dermatitis, where existing treatments leave substantial unmet need. The portfolio is designed around efficient clinical development strategies aimed at durable patient impact.
Beeline Medicines is led by an executive team with experience across drug discovery, clinical development, regulatory affairs and commercialization. Team size and funding details have not been disclosed.
